Cellectar Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value
Cellectar Biosciences, Inc. (CLRB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value of $60.65 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue · last filed 2026-03-04
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2025 was $60.65, a 14.22% increase from fiscal 2024.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2024 was $53.10, a 3665.96% increase from fiscal 2023.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2023 was $1.41, a 80.76% decline from fiscal 2022.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2022 was $7.33, a 28.14% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $60.65 10-K · filed 2026-03-04 | |
| 2024-12-31 | $53.10 10-K · filed 2026-03-04 | $1.77 10-K · filed 2025-03-13 |
| 2023-12-31 | $1.41 10-K · filed 2025-03-13 | |
| 2022-12-31 | $7.33 10-K/A · filed 2024-10-29 | |
| 2021-12-31 | $10.20 10-K · filed 2023-03-09 | $1.02 10-K · filed 2022-03-21 |
| 2020-12-31 | $1.90 10-K · filed 2022-03-21 | |
| 2019-12-31 | $3.80 10-K · filed 2021-03-02 | |
| 2018-12-31 | $15.91 10-K · filed 2020-03-09 | |
| 2017-12-31 | $11.90 10-K · filed 2019-02-26 | $1.19 10-K · filed 2018-03-21 |
| 2016-12-31 | $2.54 10-K · filed 2018-03-21 | |
| 2015-12-31 | $47.09 10-K · filed 2017-03-15 | |
| 2014-12-31 | $58.70 10-K/A · filed 2016-10-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |